Amerisource Health Services LLC has recalled 69,967 bottles of Duloxetine (duloxetine) Delayed-Release Capsules, sold under the BluePoint Laboratories brand. The recall includes 20 mg, 30 mg, and 60 mg strengths in various bottle sizes. This medication is being recalled because testing found an impurity called N-nitroso-duloxetine at levels higher than the recommended safety limits. Consumers should speak with their doctor or pharmacist before they stop taking this medication, as the risks of suddenly stopping treatment may outweigh the risks of the impurity.
N-nitroso-duloxetine is a type of nitrosamine, which is classified as a probable human carcinogen. Exposure to these impurities above safety levels over a long period of time may increase the risk of cancer.
You have 2 options:
Manufactured by Aurobindo Pharma Limited for BluePoint Laboratories.
Manufactured by Aurobindo Pharma Limited for BluePoint Laboratories.
Manufactured by Aurobindo Pharma Limited for BluePoint Laboratories.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.